David Baker’s Lab Shows Generative AI Can Design Antibodies. But Are They Good Enough to Become Drugs?


Scientists led by David Baker at the University of Washington revealed work showing they have created therapeutically active proteins from scratch. Using the lab’s generative AI model they created an antibody that neutralizes a bacterial toxin and three that target the viruses responsible for Covid-19, RSV, and the flu.

The study on bioRxiv has not been peer-reviewed, but showcases the potential power of using AI to make antibodies that target proteins just as their designers intended, rather than trawling through the blood of mice or humans in hopes of finding just the right one.